Olanzapine Pharmacokinetics: A Clinical Review of Current Insights and Remaining Questions
P Kolli, G Kelley, M Rosales, J Faden… - Pharmacogenomics …, 2023 - Taylor & Francis
Olanzapine is one of the most widely used antipsychotics since its initial approval by the US
Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study …
Food and Drug Administration in 1996 and has undergone extensive pharmacokinetic study …
[HTML][HTML] Neuroleptic medications
MA Ameer, A Saadabadi - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Objectives: Identify the mechanism of action of neuroleptics. Describe the adverse effects of
neuroleptics. Summarize the indicated and off-label use of neuroleptics. Explain …
neuroleptics. Summarize the indicated and off-label use of neuroleptics. Explain …
[PDF][PDF] Kliniske overvejelser og faldgruber ved brug af depotantipsykotika
NAW Strand, MØ Nielsen, J Nielsen - Ugeskr Læger, 2024 - content.ugeskriftet.dk
Nedsat komplians ved behandling af psykoser ses ofte og er den hyppigste årsag til
tilbagefald og genindlæggelse [1, 2]. Nedsat komplians skyldes især: bivirkninger, nedsat …
tilbagefald og genindlæggelse [1, 2]. Nedsat komplians skyldes især: bivirkninger, nedsat …